Last reviewed · How we verify
mAb Nimotuzumab
Nimotuzumab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) to inhibit tumor cell proliferation and survival.
Nimotuzumab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) to inhibit tumor cell proliferation and survival. Used for Head and neck squamous cell carcinoma, Non-small cell lung cancer, Colorectal cancer.
At a glance
| Generic name | mAb Nimotuzumab |
|---|---|
| Sponsor | National Institute of Cancerología |
| Drug class | EGFR inhibitor (monoclonal antibody) |
| Target | EGFR (Epidermal Growth Factor Receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Nimotuzumab binds to EGFR on cancer cells, preventing ligand-induced activation and downstream signaling that drives cell growth and division. This antibody-mediated blockade leads to reduced proliferation, increased apoptosis, and enhanced radiosensitivity in EGFR-expressing tumors. Unlike some other anti-EGFR agents, nimotuzumab has a lower incidence of severe skin toxicity.
Approved indications
- Head and neck squamous cell carcinoma
- Non-small cell lung cancer
- Colorectal cancer
Common side effects
- Acneiform rash
- Diarrhea
- Nausea
- Fatigue
- Infusion reactions
Key clinical trials
- Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies (PHASE2)
- HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients (PHASE2)
- Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix (PHASE2)
- Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma (PHASE2)
- Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma (PHASE2)
- Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses (PHASE2)
- Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer (PHASE2)
- Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mAb Nimotuzumab CI brief — competitive landscape report
- mAb Nimotuzumab updates RSS · CI watch RSS
- National Institute of Cancerología portfolio CI